Meropenem

Meropenem, the active ingredient in Meropenem, is a carbapenem antibiotic presented as an injectable powder for intravenous use. It is employed to treat serious bacterial infections, including complicated intra‑abdominal infections, complicated urinary tract infections, hospital‑acquired pneumonia, septicemia and bacterial meningitis, primarily in hospitalized adults and critically ill patients.

GNH USA supplies Meropenem as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides reliable cold‑chain logistics where required.

Meropenem is used to treat severe bacterial infections across several organ systems.

- Complicated intra‑abdominal infections: eradicates mixed aerobic and anaerobic pathogens causing peritonitis and intra‑abdominal sepsis. - Complicated urinary tract infections: provides broad‑spectrum coverage for resistant Gram‑negative and Gram‑positive uropathogens. - Nosocomial pneumonia: targets multidrug‑resistant organisms responsible for hospital‑acquired lung infections. - Septicemia: rapidly clears bloodstream infections caused by susceptible bacteria. - Bacterial meningitis: penetrates the cerebrospinal fluid to treat central nervous system infections.

Adverse reactions may vary in frequency and severity.

Common Side Effects: - Diarrhea: mild to moderate gastrointestinal upset. - Nausea: occasional feeling of queasiness. - Rash: transient skin erythema. - Headache: mild to moderate intensity. - Elevated liver enzymes: transient increase in hepatic transaminases. - Injection‑site pain: discomfort at the infusion site.

Serious or Rare Side Effects: - Seizures: especially in patients with renal impairment or CNS disorders. - Anaphylaxis: severe hypersensitivity reaction requiring immediate medical attention. - Clostridioides difficile colitis: antibiotic‑associated severe diarrhea. - Severe neutropenia: marked reduction in white blood cell count. - Renal toxicity: acute kidney injury in susceptible individuals.

Clinicians should consider several safety measures before and during therapy.

- Renal function: adjust dose in patients with impaired renal clearance. - Hypersensitivity: discontinue immediately if allergic reaction occurs. - Seizure risk: monitor patients with a history of seizures or CNS disorders. - Drug resistance: use according to susceptibility testing to avoid promoting resistance. - Pregnancy and lactation: evaluate risk‑benefit ratio due to limited safety data. - Store at 2‑8 °C: keep refrigerated, protect from light, do not freeze or shake.

Meropenem may interact with other medicines, requiring attention to avoid adverse outcomes.

Major Interactions (Avoid): - Valproic acid: carbapenems can reduce plasma concentrations of valproate, risking seizure breakthrough. - Other β‑lactam antibiotics: concurrent use may lead to antagonistic effects. - Probenecid: may increase meropenem plasma levels, enhancing toxicity.

Moderate Interactions (Monitor Closely): - Aminoglycosides: additive nephrotoxicity; monitor renal function. - Loop diuretics: potential electrolyte disturbances; check serum electrolytes. - Anticoagulants (e.g., warfarin): may affect INR; monitor coagulation parameters.